Cardiovascular Systems Inc
F:R7Y1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Cardiovascular Systems Inc
Income from Continuing Operations
Cardiovascular Systems Inc
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Cardiovascular Systems Inc
F:R7Y1
|
Income from Continuing Operations
-$37.9m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-62%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Income from Continuing Operations
$3.6B
|
CAGR 3-Years
58%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Income from Continuing Operations
$1.1B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Income from Continuing Operations
$3.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
15%
|
CAGR 10-Years
8%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Income from Continuing Operations
$6.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
11%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Income from Continuing Operations
$2.9B
|
CAGR 3-Years
29%
|
CAGR 5-Years
22%
|
CAGR 10-Years
17%
|
|
Cardiovascular Systems Inc
Glance View
Cardiovascular Systems, Inc. is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. The company is headquartered in St. Paul, Minnesota and currently employs 780 full-time employees. The company went IPO on 2006-06-28. The firm has developed patented orbital atherectomy systems (OAS) for both peripheral and coronary clinical applications. The primary base of its business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. Its coronary artery disease (CAD) product, the Diamondback 360 Coronary OAS (Coronary OAS), which is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.
See Also
What is Cardiovascular Systems Inc's Income from Continuing Operations?
Income from Continuing Operations
-37.9m
USD
Based on the financial report for Dec 31, 2022, Cardiovascular Systems Inc's Income from Continuing Operations amounts to -37.9m USD.
What is Cardiovascular Systems Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-62%
Over the last year, the Income from Continuing Operations growth was -31%. The average annual Income from Continuing Operations growth rates for Cardiovascular Systems Inc have been -75% over the past three years , -62% over the past five years .
